Oppenheimer Cites “Abundance of Support” for Capricor’s Deramiocel Ahead of November FDA Decision
Oppenheimer says Capricor’s Q3 update shows strong support for deramiocel in Duchenne. FDA decision expected around Nov 22; stock could hit $50.
Oppenheimer says Capricor’s Q3 update shows strong support for deramiocel in Duchenne. FDA decision expected around Nov 22; stock could hit $50.
Analysts upgraded Zentalis after DENALI Part 1b data showed median survival of 15.9 months in Cyclin E1-positive platinum-resistant ovarian cancer.
Hims & Hers stock drops after missing revenue and subscriber expectations. Q3 revenue rose 49% to $890M, but margins compressed and guidance tightened.
Shares of Abeona Therapeutics plunged after the company issued new stock for a Phase 3 EoE candidate and completed a $30 million PIPE.
Moderna lifted its 2026 revenue growth forecast to 15–25% after strong international COVID vaccine sales helped it return to profit in Q3.
CVS Health reported Q3 adjusted EPS of $2.09, topping estimates, and raised full-year guidance to at least $8.20 as it plans to split into two companies by 2028.